ClinicalTrials.gg
CompletedNCT04027361Updated Feb 18, 2022

Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 interventional study of Amphetamine Extended Release (ER) Tablet 20 mg in ADHD, sponsored by Tris Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
448th of 706
41 · median 70
Started
2019
with 31 others
Phase 2
80 of 807
3 open now
Registered
569th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 448th largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 80 in phase 2, and was the 569th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.

Read the detailed description

At a single US-based study site, a driving simulation will be used to assess the effect on driving performance for the co-primary endpoints, study subjects' driving performance at 45 minutes and 10 hours post-dose, compared with placebo. Eligible subjects will be prescreened for ADHD but otherwise healthy, aged 18-25 years.

Driving simulations that simulate common driving events to which the study subject must react. The reactions to each event will be assessed. Using a parallel-group design, subjects will be assessed while on study drug, and while on placebo.

Safety assessments will include spontaneously reported treatment-emergent adverse events and vital signs at 4 hours post-dose.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 to 25 years, inclusive, at the time of screening who have a valid driver's license.
  2. Normal visual acuity (either uncorrected or corrected with glasses, contact lenses or surgery) at Screening based upon clinical assessment of the Investigator
  3. Diagnosed with ADHD using the Version 5 (DSM-5) criteria based on ADHD module from the Mini-International Neuropsychiatric Interview (M.I.N.I) version 7.0.2.
  4. IQ within normal range based upon clinical assessment of the Investigator.
  5. For female participants, presently using an acceptable method of based upon clinical assessment of the Investigator.
  6. Willing to abstain from using any forms of cannabinoids (THC, CBD, hemp oil, etc.) for 2 weeks prior to the Driving Simulation Visit (if applicable).
  7. Be able to understand, read, write, and speak English fluently to complete the study related materials.
  8. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Current or lifetime history of bipolar disorder or any psychotic disorder.
  2. Current active symptoms of major depression generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder based upon clinical assessment of the Investigator.
  3. Known history of chronic medical illnesses including known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, and known family history of sudden death.
  4. History of uncontrolled hypertension or a resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg. Patients with well-controlled hypertension on a stable dose for at least 3 months of anti-hypertensives will be allowed to participate.
  5. Have findings in vital signs measurements at Screening including:

    • Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg (average of triplicate measurements)
    • Heart rate >100 bpm (average of triplicate measurements)
  6. Known history or presence of significant renal or hepatic disease.
  7. Use of monoamine oxidase inhibitors (MAOI), e.g. selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue, within 14 days of the Driving Simulator Visit.
  8. Use of ADHD medications including all stimulants (methylphenidate, amphetamine or derivatives of any of these products), within 48 hours of the Driving Simulator Visit.
  9. Participation in a clinical study in which an drug was administered within 30 days prior to Screening.
  10. Known history of allergy/ to amphetamine or any of the components of the test products.
  11. Known history of lack of clinical response to amphetamine based upon Investigator assessment
  12. Any uncontrolled medical condition that, in the opinion of Medical Monitor or Sponsor, would preclude study participation.
  13. History or presence of alcohol dependence or substance abuse disorder or within the last 6 months based upon clinical assessment of the Investigator.
  14. Positive urine pregnancy test at Driving Simulator Visit
  15. Positive breath alcohol test at Driving Simulator Visit.
  16. Patient's inability or unwillingness to follow directions from the study research staff.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Active comparator
    Amphetamine ER Tablets, 20 mg

    Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline

    Drug: Amphetamine Extended Release (ER) Tablet 20 mg

  • Placebo comparator
    Placebo

    Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline

    Drug: Amphetamine Extended Release (ER) Tablet 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Composite Reaction Time Score

    Measurement of reaction time across a series of driving simulations

    Time frame: Measured at pre-dose, 45 minutes and 3 hours post-dose

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2021, 24 months.

Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 24 months is above that.

Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Jul 22, 2019
StartActual
Oct 1, 2019
Primary completionActual
Oct 15, 2021
CompletionActual
Oct 15, 2021
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04027361
Lead sponsor
Tris Pharma, Inc.
Collaborators
Massachusetts General Hospital, Massachusetts Institute of Technology
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Oct 1, 2019
Primary completion
Oct 15, 2021
Completion
Oct 15, 2021
Last update
Feb 18, 2022

Study contacts

Joseph Biederman, MD
principal investigator · Massachusetts General Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphetamine

Start the discussion